New Zealand markets closed

LLY Jun 2024 450.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
10.400.00 (0.00%)
As of 01:41PM EST. Market open.
Full screen
Previous close10.40
Expiry date2024-06-21
Day's range9.80 - 10.40
Contract rangeN/A
Open interestN/A
  • Yahoo Finance Video

    Weight loss drugs likely to boost apparel stocks: Survey

    The market for GLP-1 weight loss drugs such as Wegovy and Ozempic have captured Wall Street's attention. A consumer survey carried out by Stifel Financial (SF) found 15% of respondents currently use a GLP-1 drug while an additional 21% said they would be interested if it were FDA approved with proven results. Stifel Analyst Jim Duffy joins Yahoo Finance to discuss how the uptake of weight loss drugs could prompt a shift in spending trends and the greater impact of GLP-1's across industries. "We do expect that there will be less calories consumed, by the projections of our food & beverage team, get to 4% less calories consumed with this adoption. We do think that there's going to be more apparel spend," Duffy says. "Consumers are losing significant amounts of weight on these drugs, some clinical trials, including one released recently from Mounjaro, speaks to greater than 40% of consumers losing more than 10% of their body weight." Duffy names Lululemon (LULU), Dick's Sporting Goods (DKS) and Levi's (LEVI) as potential winners. Click here to watch the full interview on the Yahoo Finance YouTube page or you can watch this full episode of Yahoo Finance Live here.

  • Zacks

    The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

    AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

  • Motley Fool

    Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?

    Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy.